De novo designed proteins neutralize lethal snake venom toxins.
Julien S BakerSusana Vazquez TorresMelisa Benard ValleStephen P MackessyStefanie K MenziesNicholas R CasewellShirin AhmadiNick J BurletEdin MuratspahićIsaac SappingtonMax OverathEsperanza Rivera-de-TorreJann LedergerberAndreas Hougaard LaustsenKim BoddumAsim K BeraAlex KangEvans BrackenbroughIara CardosoEdouard CrittendenRebecca EdgeJustin DecarreauRobert RagotteArvind S PillaiMohamad AbediHannah L HanStacey R GerbenAnalisa MurrayRebecca SkotheimLynda StuartLance J StewartThomas FryerTimothy Patrick JenkinsPublished in: Research square (2024)
Snakebite envenoming remains a devastating and neglected tropical disease, claiming over 100,000 lives annually and causing severe complications and long-lasting disabilities for many more 1,2 . Three-finger toxins (3FTx) are highly toxic components of elapid snake venoms that can cause diverse pathologies, including severe tissue damage 3 and inhibition of nicotinic acetylcholine receptors (nAChRs) resulting in life-threatening neurotoxicity 4 . Currently, the only available treatments for snakebite consist of polyclonal antibodies derived from the plasma of immunized animals, which have high cost and limited efficacy against 3FTxs 5,6,7 . Here, we use deep learning methods to de novo design proteins to bind short- and long-chain α-neurotoxins and cytotoxins from the 3FTx family. With limited experimental screening, we obtain protein designs with remarkable thermal stability, high binding affinity, and near-atomic level agreement with the computational models. The designed proteins effectively neutralize all three 3FTx sub-families in vitro and protect mice from a lethal neurotoxin challenge. Such potent, stable, and readily manufacturable toxin-neutralizing proteins could provide the basis for safer, cost-effective, and widely accessible next-generation antivenom therapeutics. Beyond snakebite, our computational design methodology should help democratize therapeutic discovery, particularly in resource-limited settings, by substantially reducing costs and resource requirements for development of therapies to neglected tropical diseases.